Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MAGEA1 is a member of the MAGEA gene family. Additionally we are shipping Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) Kits (16) and Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) Proteins (9) and many more products for this protein.
Showing 10 out of 116 products:
Human Polyclonal MAGEA1 Primary Antibody for EIA, IHC (p) - ABIN358644
Suyama, Ohashi, Nagai, Hatano, Asano, Murate, Saito, Kinoshita: The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. in Leukemia research 2002
Show all 5 references for 358644
Human Polyclonal MAGEA1 Primary Antibody for WB - ABIN2782493
Ries, Vairaktaris, Mollaoglu, Wiltfang, Neukam, Nkenke: Expression of melanoma-associated antigens in oral squamous cell carcinoma. in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2008
Human Polyclonal MAGEA1 Primary Antibody for IHC (p), WB - ABIN390105
Celis, Fikes, Wentworth, Sidney, Southwood, Maewal, Del Guercio, Sette, Livingston: Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. in Molecular immunology 1995
In patients with Colon cancer, the expression of MAGE (show MAGEB10 Antibodies)-A(1-6) gene was associated with a poor prognosis.
MAGEA1 was expression in 15% of synovial sarcomas and was not associated with prognosis.
Data show that overall survival (OS) was significantly lower for patients expressing pan (show SUPT6H Antibodies)-MAGE (show MAGEB10 Antibodies) or MAGE (show MAGEB10 Antibodies)-A1/A3/A4 in both independent cohorts.
These data demonstrate that MAGE (show MAGEB10 Antibodies)-A1-, MAGE-A3 (show MAGEA3 Antibodies)-, and NY-ESO-1 (show CTAG1B Antibodies)-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible.
The MAGE-D4 (show MAGED4 Antibodies) polyclonal antibody with high specificity and sensitivity has been successfully prepared.
up-regulation of MAGE (show MAGEB10 Antibodies)-A1 dramatically promoted proliferation, migration, and invasion of human melanoma cell lines in vitro
Preoperative serum MAGED4 (show MAGED4 Antibodies) was significantly higher in esophageal squamous cell carcinoma patients than in controls.
The overall survival of laryngeal squamous cell carcinoma patients with positive MAGE-A1, MAGE-A9, or MAGE-A11 expression was lower than the patients without MAGE-A1, MAGE-A9, or MAGE-A11 expression.
MAGE (show MAGEB10 Antibodies)-A is more highly expressed than NY-ESO-1 (show CTAG1B Antibodies) in a majority of human malignancies
TRIM31 (show TRIM31 Antibodies) directly binds to NSE4, suggesting the existence of a TRIM31 (show TRIM31 Antibodies)-MAGEA1-NSE4 complex reminiscent of the NSE1 (show FAM84A Antibodies)-NSE3 (show NDNL2 Antibodies)-NSE4 trimer.
May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex.
, antigen MZ2-E
, cancer/testis antigen 1.1
, cancer/testis antigen family 1, member 1
, melanoma antigen MAGE-1
, melanoma antigen family A 1
, melanoma-associated antigen 1
, melanoma-associated antigen MZ2-E
, MAGE-D4 antigen
, MAGE-E1 antigen
, melanoma-associated antigen D4